UPDATE: H.C. Wainwright Maintains Neutral On Nektar Therapeutics, Raises Target To $32 As Firm Notes 'Upward Bias Exiting SITC'; 'Durability in frontline melanoma is reassuring, but we remain wary'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · 11/11/2019 16:56